Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Financial Statements Details

v3.25.1
Consolidated Financial Statements Details
12 Months Ended
Dec. 31, 2024
Consolidated Financial Statement Details  
Consolidated Financial Statement Details

3. Consolidated Financial Statement Details

Equity Securities

As of December 31, 2024 and 2023, investment in equity securities was $3.5 million and $0.2 million, respectively. For the years ended December 31, 2024 and 2023, the Company recognized a gain of $0.1 million and a loss of $0.2 million, respectively, due to the change in fair value of its investment in equity securities in the other income (expense), net line item of the consolidated statements of operations.

Intangible Assets, Net

The following table summarizes the cost, accumulated amortization, and net carrying value of the Company’s intangible assets as of December 31, 2024 (in thousands):

Accumulated

Net Carrying

Cost

Amortization

Value

As of December 31, 2024

Pulmokine - Seralutinib IP (Note 4)

$

26,115

$

206

$

25,909

Total intangible assets

$

26,115

$

206

$

25,909

The following table summarizes the cost, accumulated amortization, impairment charge, and net carrying value of the Company’s intangible assets as of December 31, 2023 (in thousands):

Accumulated

Impairment

Net Carrying

Cost

Amortization

Charge (1)

Value

As of December 31, 2023

Obseva - Ebopiprant IP (Note 4)

$

15,247

$

994

$

14,253

$

Total intangible assets

$

15,247

$

994

$

14,253

$

(1)As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million for the Ebopiprant IP was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheets and included a $14.2 million impairment charge in the consolidated statements of operations.

The estimated remaining life of the intangible assets is 12 years. The following table presents the projected amortization expense for the next five years (in thousands):

Intangible Asset

    

Amortization

2025

$

2,176

2026

 

2,176

2027

2,176

2028

2,176

2029

2,176

Total

$

10,880

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

December 31, 

December 31, 

    

2024

    

2023

Accrued short-term interest payable

$

3,039

$

535

Accrued incentive compensation

1,555

1,203

Accrued clinical liabilities

306

Income taxes payable in connection with Pulmokine acquisition

280

Accrued legal and accounting fees

251

791

Accrued payroll and benefits

170

149

Other accrued liabilities

 

151

 

90

Total

$

5,752

$

2,768

Arbitration Proceeding

In June 2021, the Company initiated a binding arbitration proceeding with one of its licensees (the “Licensee”) at the American Arbitration Association/International Centre for Dispute Resolution, and sought milestone and royalty payments under its license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, the Company received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award the Company damages and ruled that the license agreement had expired. The panel ruled that the Company was responsible for the Licensee’s costs as well as arbitrators’ fees and administrative fees previously incurred by the Licensee of $4.1 million, which the Company paid in April 2023.